{"id":40675,"date":"2023-02-15T06:52:20","date_gmt":"2023-02-15T07:52:20","guid":{"rendered":"https:\/\/peymantaeidi.net\/stem-cell\/?p=40675"},"modified":"2023-02-15T08:37:22","modified_gmt":"2023-02-15T08:37:22","slug":"clene-nasdaqclnn-stock-rating-reaffirmed-by-hc-wainwright","status":"publish","type":"post","link":"https:\/\/peymantaeidi.net\/stem-cell\/2023\/02\/15\/clene-nasdaqclnn-stock-rating-reaffirmed-by-hc-wainwright\/","title":{"rendered":"Clene (NASDAQ:CLNN) Stock Rating Reaffirmed by HC Wainwright"},"content":{"rendered":"

\"CleneClene (NASDAQ:CLNN<\/a> \u2013 Get Rating<\/a>)<\/span>\u2018s stock had its \u201cbuy\u201d rating reiterated by HC Wainwright in a research report issued on Monday, Benzinga<\/a> reports. They presently have a $15.00 price target on the stock.<\/p>\n

Separately, Roth Capital reissued a \u201cbuy\u201d rating on shares of Clene in a research report on Monday, February 6th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company\u2019s stock. According to MarketBeat, the company has a consensus rating of \u201cModerate Buy\u201d and an average target price of $11.80.<\/p>\n

Clene Trading Down 4.8 %<\/h2>\n

Shares of NASDAQ:CLNN<\/a> opened at $1.38 on Monday. The business has a 50-day moving average price of $1.24 and a 200 day moving average price of $1.84. The company has a market capitalization of $101.87 million, a price-to-earnings ratio of -3.63 and a beta of 0.36. Clene has a 12-month low of $0.87 and a 12-month high of $5.13. <\/p>\n

Institutional Trading of Clene<\/h2>\n

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Tang Capital Management LLC acquired a new position in Clene in the 3rd quarter valued at about $3,080,000. Vanguard Group Inc. grew its position in Clene by 14.7% in the 3rd quarter. Vanguard Group Inc. now owns 931,613 shares of the company\u2019s stock valued at $2,609,000 after acquiring an additional 119,084 shares in the last quarter. State Street Corp grew its position in Clene by 2.3% in the 1st quarter. State Street Corp now owns 903,885 shares of the company\u2019s stock valued at $3,561,000 after acquiring an additional 20,627 shares in the last quarter. Millennium Management LLC acquired a new position in Clene in the 2nd quarter valued at about $620,000. Finally, Geode Capital Management LLC grew its position in Clene by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 230,805 shares of the company\u2019s stock valued at $230,000 after acquiring an additional 9,614 shares in the last quarter. 5.86% of the stock is owned by institutional investors and hedge funds. <\/p>\n

About Clene<\/h2>\n

(Get Rating<\/a>)<\/p>\n

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2\/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases.<\/p>\n

Recommended Stories<\/h2>\n

\"Analyst<\/p>\n

Receive News & Ratings for Clene Daily<\/strong> – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Clene and related companies with MarketBeat.com’s FREE daily email newsletter<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Clene (NASDAQ:CLNN \u2013 Get Rating)\u2018s stock had its \u201cbuy\u201d rating reiterated by HC Wainwright in<\/p>\n","protected":false},"author":1,"featured_media":22379,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/posts\/40675"}],"collection":[{"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/comments?post=40675"}],"version-history":[{"count":3,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/posts\/40675\/revisions"}],"predecessor-version":[{"id":40678,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/posts\/40675\/revisions\/40678"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/media\/22379"}],"wp:attachment":[{"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/media?parent=40675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/categories?post=40675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/tags?post=40675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}